FDA assigns Fast Track Designation to AQST-108 (sublingual film formulation delivering systemic epinephrine) for treatment of allergic reactions including anaphylaxis

Company expects to commence its first pharmacokinetic study of AQST-108, a “first of its kind” oral sublingual film formulation delivering systemic epinephrine, comparing it to epinephrine administered as subcutaneous and intramuscular injection.

Source:

Biospace Inc.